NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have
commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead
plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links
provided. There is no cost or obligation to you.
Cocrystal Pharma, Inc. (NASDAQCM: COCP)
Class Period: September 23, 2013 - September 7, 2018
Lead Plaintiff Deadline: November 19, 2018
Join the action: https://www.zlk.com/pslra-1/cocrystal-pharma-inc-loss-form?wire=3
The lawsuit alleges: Cocrystal Pharma, Inc. made materially false and/or misleading statements throughout the class period
and/or failed to disclose that: (1) defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal’s stock
price; (2) this illicit scheme would result in governmental scrutiny, including from the SEC; (3) defendants failed to abide by SEC
disclosure regulations; and (4) as a result, defendants’ statements about Cocrystal’s business, operations and prospects were
materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the Cocrystal Pharma, Inc. class action contact jlevi@levikorsinsky.com.
TG Therapeutics, Inc. (NASDAQCM: TGTX)
Class Period: June 4, 2018 - September 25, 2018
Lead Plaintiff Deadline: December 3, 2018
Join the action: https://www.zlk.com/pslra-1/tg-therapeutics-inc-loss-form?wire=3
The lawsuit alleges that, during the class period, TG Therapeutics, Inc. made materially false and/or misleading statements
and/or failed to disclose that: (1) TG was involved in cleaning the data collected in the UNITY-CLL Trial; and as a result, was
able to gain an understanding as to the efficacy of the combination therapy; (2) as a result of that data cleaning, TG knew the
UNITY-CLL Trial had failed to meet its stated goal and as a result, the Company would not be able to seek accelerated approval; and
(3) given that the UNITY-CLL Trial had failed to meet its stated goal, it was highly unlikely that the combination therapy would
meet its primary endpoint of increased progression free survival.
To learn more about the TG Therapeutics, Inc. class action contact jlevi@levikorsinsky.com.
Stitch Fix, Inc. (NASDAQ: SFIX)
Class Period: June 8, 2018 - October 1, 2018
Lead Plaintiff Deadline: December 10, 2018
Join the action: https://www.zlk.com/pslra-1/stitch-fix-inc-loss-form?wire=3
The lawsuit alleges: Stitch Fix, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1)
Stitch Fix’s active client growth had slowed to a crawl; (2) Stitch Fix had completely shut down its television advertising
campaign for 10 of the 13 weeks in fourth quarter 2018, dramatically decreasing the number of new active client additions; and (3)
as a result, the Company’s current business metrics and financial prospects were not as strong as it had led the market to believe
during the Class Period.
To learn more about the Stitch Fix, Inc. class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any
recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys
have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of
dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
